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UDP-glucuronosyltransferases (UGTs) are important phase II drug metabolism enzymes.
The aim of this study was to explore the relationship between age and changes
in mRNA expression and activity of major human hepatic UGTs, as well as to
understand the potential regulatory mechanism underlying this relationship. Using
previously generated data, we investigated age-dependent mRNA expression levels of
11 hepatic UGTs (UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A9, UGT2B4,
UGT2B7, UGT2B10, UGT2B15, and UGT2B17) and 16 transcription factors (AHR, AR,
CAR, ESR2, FXR, GCCR, HNF1a, HNF3a, HNF3b, HNF4a, PPARA, PPARG, PPARGC,
PXR, SP1, and STAT3) in liver tissue of donors (n = 38) ranging from 0 to 25 years of
age. We also examined the correlation between age and microsomal activities using
14 known UGT drug substrates in the liver samples (n = 19) of children donors.
We found a statistically significant increase (nominal p < 0.05) in the expression of
UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT2B7, and UGT2B17, as well
as glucuronidation activities of serotonin, testosterone, and vorinostat during the first
25 years of life. Expression of estrogen receptor 1 and pregnane X receptor, two
strong UGT transcriptional regulators, were significantly correlated with both age and
UGT mRNA expression (p ≤ 0.05). These results suggest that both UGT expression
and activity increase during childhood and adolescence, possibly driven in part by
hormonal signaling. Our findings may help explain inter-patient variability in response
to medications among children.
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INTRODUCTION
UDP-glucuronosyltransferases (UGTs) are a family of enzymes that make significant contributions
to the hepatic metabolism of exogenous (e.g., drugs) and endogenous (e.g., bilirubin, testosterone,
serotonin) substances, as well as numerous environmental pollutants, dietary chemicals, and
chemical carcinogens. They also metabolize phase I oxidation products. UGTs catalyze the transfer
of glucuronic acid from UDP glucuronic acid, causing the compounds or metabolites to undergo
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renal and biliary excretion. Drugs administered for therapeutic
purpose exhibit variability in metabolism due to differing
function and expression of these genes (Radominska-Pandya
et al., 1999).
The regulation of UGT enzyme expression is complex and
involves cis-factors (i.e., polymorphisms), trans-factors [such as
transcription factors (TFs) and nuclear receptors (NRs)], miRNA
targeting, and other epigenetic regulating factors (Bigo et al.,
2013; Dluzen et al., 2014; Liu et al., 2014; Oda et al., 2014).
In the liver, transcription levels of UGTs help determine their
activity (Liu et al., 2014). Thus far, numerous polymorphisms
have been identified that regulate UGT gene transcription. In
addition, the tissue-specific and ligand activated TFs and NRs
play a primary role in constitutive and inducible expression
of UGTs by binding to cis-regulatory elements (CREs) (Liu
et al., 2014). These regulators include constitutive androstane
receptor (CAR), pregnane X receptor (PXR), hepatocyte nuclear
factor 4 alpha (HNF4a), xenobiotic-activated aryl hydrocarbon
receptor (AhR), and estrogen receptor (ESR1) (Bigo et al., 2013;
Kalthoff et al., 2013; Hu et al., 2014; Liu et al., 2014). The
inter-individual variability in expression of UGT family members
contributes to the variability in response and toxicity of many
medications.
Among children, however, the ontogeny of drug-metabolizing
enzymes is paralleled by maturation of organ systems, and has
profound effects on drug disposition in addition to being a
principal factor for age-associated changes in drug clearance
especially in fetal life and in the first months of postnatal life
(Johnson, 2003; Blake et al., 2005; Dotta and Chukhlantseva,
2012; Fanni et al., 2014). Therefore, both age and genetic
variation confer the variability in activity and expression of
drug metabolizing enzymes among children. Ontogeny of several
UGT enzymes has been explored with limited amounts of
liver samples. It has been long found that several of the
UGT enzymes experience changes in expression and/or activity
from early gestational age and may not reach adult levels
(Onishi et al., 1979; Leakey et al., 1987; Zaya et al., 2006;
Miyagi and Collier, 2007, 2011; Miyagi et al., 2012; Divakaran
et al., 2014). However, most previous studies were limited
by fragmented data from different sample sets, which made
it difficult to compare data between studies. The constant
change of UGT gene expression and activity in human livers
across childhood and adolescence has not been comprehensively
investigated. In addition, while ontogenic UGT expression
has been observed, no study has aimed at understanding
the molecular mechanism underlying the age-related gene
regulation.
We hypothesize that an empirical, pathway-based analysis of
the age-dependent expression and activity of hepatic UGTs will
allow us to perform a detailed comparison between these genes.
We also postulate that hormonal regulation of UGTs may be
a major reason for their age-dependent expression. This study
aims to comprehensively examine the pattern of age-dependent
mRNA expression and microsomal activities of all major hepatic
UGT isoforms in human livers from individuals between 0 and
25 years old. Meanwhile, in order to understand the regulatory
mechanism of UGT ontogeny, we also aim to examine the
interrelationship between age and mRNA expression of 16 UGT
regulatory TFs, and between the expression of relevant TFs (ESR1
and PXR) and all UGTs. Such information is significant since it
may influence therapeutic choices and dosing recommendations
in the pediatric population.
MATERIALS AND METHODS
Liver Tissue Samples and Data
Collection
Human liver tissue samples (n = 38, 0–25 years old, 10 females,
28 males) from donor organs unsuitable for transplantation
were described in previous studies (Gamazon et al., 2013;
Liu et al., 2014). All donors are of Caucasian origin. The
mRNA expression level of genes including 11 hepatic UGTs
(UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A9,
UGT2B4, UGT2B7, UGT2B10, UGT2B15, and UGT2B17) and
16 TFs (AHR, AR, CAR, ESR2, FXR, GCCR, HNF1a, HNF3a,
HNF3b, HNF4a, PPARA, PPARG, PPARGC, PXR, SP1, and
STAT3) had been previously quantified with real-time PCR (Liu
et al., 2014). Among these livers (n = 38), 19 were previously
characterized for liver microsomal glucuronidation activity
using 14 UGT substrates [substrates and major UGTs involved
in their metabolism: SN-38 (UGT1A1, UGT1A9, UGT1A3,
and UGT1A6), bilirubin (UGT1A1), thyroxine (UGT1A3
and UGT1A1), serotonin (UGT1A6), flavopiridol (UGT1A9),
mycophenolic acid (UGT1A9), S-oxazepam (UGT2B15,
UGT2B7, UGT1A1, and UGT1A6), testosterone (UGT2B17
and UGT2B15), epirubicin (UGT2B7), morphine (UGT2B7,
UGT1A1, UGT1A3, UGT1A6, UGT1A8, UGT1A9, and
UGT1A10), anastrozole (UGT1A4, UGT1A3, and UGT2B7),
imipramine (UGT1A4 and UGT2B10), acetaminophen
(UGT1A9, UGT1A1, UGT2B15, UGT1A6 and UGT2B7),
and vorinostat (UGT2B17, UGT2B7, and UGT1A9)] (Liu et al.,
2014). Data were obtained from a previously published study
(Liu et al., 2014) and used for subsequent analyses. This study
was originally approved by the Institutional Review Boards
(IRBs) of The University of Chicago and Purdue University.
Statistical Analysis
Age-related gene expression can be non-linear, to determine the
best model to assess age-dependent UGT gene expression or
activity, we first investigated the polynomial regression including
the quadratic term of age (age2) for all UGT genes. Interestingly,
age2 showed a marginally significant effect only on UGT1A1 gene
(p = 0.01), and the significance disappeared after controlling
multiple comparison. For all other UGT genes, the raw p values of
the effects of age2 range from 0.08 to 0.97. Given all these results,
the linear model was employed for the final analysis as presented
in the manuscript.
Correlation between age and expression of each of the
UGT genes and glucuronidation activities were then tested
using a linear regression model by including sex as a
covariate. Correlation between mRNA expression levels of UGTs
and TFs as well as between expression of UGTs and their
substrates’ glucuronidation rates were performed based on
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Pearson’s correlation. With the transformed data, the normality
assumption is satisfied. Although the sample size is relatively
small, the relationship is approximately linear as tested above.
Therefore, we prefer the more powerful Pearson’s correlation
over the non-parametric test in our analysis.
The Benjamini–Hochberg’s false discovery rates (FDR) were
used to control multiple testing. An FDR ≤ 0.05 was used as cut-
off to correct for multiple testing. A nominal p ≤ 0.05 indicates
a “suggestive” correlation. Statistical analyses were carried out
using SPSS 23.0 (SPSS, Inc., Chicago, IL, USA), and data were
plotted using Graphpad Prism 7.0 (GraphPad Prism, La Jolla, CA,
USA).
RESULTS
Correlation between Age and UGT
mRNA Expression
The relationship between UGT gene expression and age was
assessed using a linear regression model controlling for gender
information. Of the 11 hepatic UGTs quantified using real-
time PCR, 6 (UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A6,
UGT2B7, and UGT2B17) showed a statistically significant
(nominal p < 0.05) increase in expression in 38 donors between
the ages of 0 and 25 years (Table 1). After adjusting for multiple
testing, changes in UGT1A3, UGT1A4, UGT1A5, UGT1A6, and
UGT2B17 mRNA expression remained significant (FDR < 0.05).
It is plausible that the mRNA levels of UGTs are higher after
15 years of age (Figure 1 shows the expression levels of UGT1A6
and UGT2B17 as examples). A post hoc t-test used to test the
difference in gene expression between younger (0–15 year) and
older children (16–25 year) demonstrated that older children
have on average >2-fold higher expression levels of most UGTs
that change with age (UGT1A1, UGT1A3, UGT1A4, UGT1A5,
UGT1A6, and UGT2B17) (post hoc t-test, p < 0.02 for all tests)
(Table 1).
TABLE 1 | Correlation between age and hepatic
UDP-glucuronosyltransferase (UGT) transcription among children.
Gene β p-value FDR ∗Fold change ∗p-value
UGT1A1 0.354 0.04 0.063 2.19 0.014
UGT1A3 0.514 0.002 0.006 2.88 0.015
UGT1A4 0.557 0.001 0.006 3.17 0.003
UGT1A5 0.445 0.008 0.018 2.7 0.003
UGT1A6 0.513 0.002 0.006 2.91 0.014
UGT1A9 0.335 0.053 0.073
UGT2B4 0.224 0.201 0.221
UGT2B7 0.355 0.039 0.063
UGT2B10 0.25 0.16 0.196
UGT2B15 0.125 0.471 0.471
UGT2B17 0.521 0.002 0.006 5.53 <0.001
Both nominal and false discovery rates (FDR)-corrected p-values are shown.
Statistically significant values are shown in bold.
∗Fold changes and p-values were calculated for the post hoc t-test for comparison
of mRNA expression levels between young (0–15 years) and old (16–25 years)
children groups.
Intercorrelation between Age, UGT
Expression, and Microsomal Activity
Microsomal glucuronidation activities of 14 UGT substrates
were previously quantified in a subset of the aforementioned
liver tissues. The glucuronidation activities of three substrates
(serotonin, testosterone, and vorinostat) were nominally
associated with age (p < 0.05) after controlling for gender
(Table 2). After FDR adjustment, the change in serotonin
glucuronidation remained significant (FDR < 0.05) (Figure 2
shows serotonin and testosterone glucuronidation as examples).
Serotonin is metabolized by UGT1A6, and UGT2B17 is the
major UGT involved in the metabolism of both testosterone
and vorinostat (Liu et al., 2014). Similar to the gene expression
results for UGT1A6 and UGT2B17, children older than 15 years
old demonstrated more than twofold higher serotonin and
testosterone glucuronidation activity compared to the younger
children (post hoc t-test, p< 0.05, Table 2).
To investigate whether the increase in gene expression
might cause increased enzyme activity, we further tested
the correlations between UGT1A6 or UGT2B17 expression
and serotonin or testosterone activities, respectively. Strong
correlations between UGT mRNA expression and their
corresponding activities were observed (Pearson’s r > 0.8,
p < 0.0001 for both pairs) (Table 2). Both correlations remained
significant after controlling for age and sex in a multivariate
analysis (p< 0.001, data not shown).
Interrelationship between mRNA
Expression of UGTs, TFs, and Age
In order to understand the potential regulatory mechanism
underlying the age-related UGT transcription, we specifically
examined the association between ESR1 or PXR expression and
all hepatic UGT expression among the children livers. Nominally,
ESR1 and PXR were found to be the only TFs whose expression
was significantly correlated with age (p ≤ 0.05 for both, data not
shown). However, this association was not significant after FDR
adjustment (FDR > 0.05, data not shown). Nevertheless, there
were significant correlations between ESR1 or PXR expression in
the pediatric livers and that of nearly every UGT gene, even after
FDR adjustment (Table 3).
DISCUSSION
The ontogenic expression and regulation of UGT genes remain
incompletely understood. We performed a comprehensive survey
of the age-dependent mRNA expression and activity of UGTs in
livers of children from 0 to 25 years of age. Our study suggested
that regulation of a few UGTs (in particular UGT1A6 and
UGT2B17) is significantly impacted by age, and these changes
may be partly driven by hormonal signaling during development.
While many other factors also impact the expression and activity
of UGT enzymes (such as medications, supplements, alcohol
consumption, and smoking), our findings may help explain some
of the inter-patient variability in drug metabolism in pediatric
populations.
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FIGURE 1 | Correlation between age and UGT gene expression with UGT1A6 (A) and UGT2B17 (B) as examples. UGT gene expression were quantified with
real-time PCR and normalized to the expression of beta-actin gene. Data were plotted as the +log2 transformed relative ratios (UGT/housekeeping gene).
TABLE 2 | Correlation between age and microsomal glucuronidation activity of UGT substrates.
Drug β p-value FDR ∗Fold change ∗p-value aUGT1A6 aUGT2B17
r p r p
Bilirubin 0.193 0.467 0.569
Serotonin 0.742 0.002 0.028 3.78 0.039 0.81 5.40E − 05 0.44 0.06
SN-38 −0.19 0.488 0.569
Flavopiridol 0.393 0.159 0.334
Thyroxine 0.304 0.267 0.467
Epirubicin −0.1 0.722 0.778
Morphine −0.06 0.83 0.830
S-Oxazepam −0.2 0.476 0.569
Testosterone 0.609 0.017 0.119 2.19 0.003 0.21 0.42 0.83 1.60E − 05
Mycophenolic acid 0.416 0.162 0.334
Vorinostat 0.522 0.047 0.219
Acetaminophen 0.389 0.153 0.334
Anastrozole 0.281 0.304 0.473
Imipramine 0.377 0.167 0.334
The correlation coefficient (r) and p-value of Pearson’s correlation are shown. Statistically significant values are shown in bold.
∗Fold changes and p-values were calculated for the post hoc t test for comparison of glucuronidation activity between young (0–15 years) and old (16–25 years) children
groups.
aCorrelation between UGT mRNA expression and microsomal substrate glucuronidation rate among livers.
Ontogeny of UGTs in humans has been explored previously,
particularly between pre- and post-natal livers and between
children and adult human livers (Burchell et al., 1989; Strassburg
et al., 2002; Zaya et al., 2006; Miyagi and Collier, 2007, 2011;
Miyagi et al., 2012; Divakaran et al., 2014). For the first time to
our knowledge, our study explored the age-dependent mRNA
expression and microsomal activity of all major hepatic UGTs
in a single sample set with an age range encompassing both
childhood and adolescence. We found that a few UGTs, especially
UGT1A6 and UGT2B17, have more significant age-dependent
transcription. This is consistent with the correlation between age
and level of glucuronidation activity of UGT1A6 and UGT2B17.
These age dependent changes in UGT expression and activity are
particularly observed between the childhood group (0–15 years)
and adolescent or young adult group (16–25 years), with a
more than twofold change on average in both expression and
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FIGURE 2 | Correlation between age and UGT substrate glucuronidation rates in children liver microsomes: (A) serotonin; (B) testosterone.
Glucuronidation rates (+log2 transformed) of UGT substrates had been previously determined (Kang et al., 2010; Liu et al., 2014).
TABLE 3 | Correlation (Pearson’s correlation) between gene expression of UGT and both pregnane X receptor (PXR) and estrogen receptor (ESR1)
among children livers.
UGT genes PXR ESR1
r p FDR r p FDR
UGT1A1 0.503 0.001 0.0018 0.375 0.02 0.022
UGT1A3 0.299 0.073 0.081 0.287 0.085 0.085
UGT1A4 0.521 0.001 0.0018 0.597 7.6E − 05 2.8E − 04
UGT1A5 0.455 0.004 0.0055 0.553 3.2E − 04 8.8E − 04
UGT1A6 0.619 4.4E − 05 4.8E − 04 0.448 0.005 0.0092
UGT1A9 0.455 0.004 0.0055 0.431 0.007 0.0096
UGT2B4 0.548 3.7E − 04 0.0014 0.43 0.007 0.0096
UGT2B7 0.557 2.8E − 04 0.0014 0.672 4.0E − 06 2.20E − 05
UGT2B10 0.503 0.001 0.0018 0.724 4.2E − 07 4.62E − 06
UGT2B15 0.171 0.305 0.305 0.468 0.003 0.0066
UGT2B17 0.318 0.055 0.067 0.38 0.02 0.022
Correlation coefficient (r), p-value and FDR-corrected p-value are shown. Statistically significant values are shown in bold.
enzyme activity observed between the two age groups. This
indicates that pharmacokinetics of therapeutic drugs that are
substrates of UGT1A6 and UGT2B17 may change with age, and
younger children may have slower intrinsic clearance of these
drugs.
Previous studies have demonstrated that protein expression
or activities of a few hepatic UGTs are significantly related to
age, e.g., UGT1A1, UGT1A4, UGT1A6, UGT2B7, UGT1A9, and
UGT2B15 (Zaya et al., 2006; Miyagi and Collier, 2007, 2011;
Miyagi et al., 2012; Divakaran et al., 2014). However, major
changes of these enzyme expression or activity were observed
among the early stage of the development. Our samples are
mainly children older than 1 year of age, which does not allow
for an assessment for the changes at the early developmental
stage. Zaya et al. (2006) observed a significant increase in both
protein expression and enzyme activity of UGT2B7 along with
age in children across the entire developmental process, we
also observed a weak correlation between age and UGT2B7
mRNA expression in our samples (nominal p = 0.039, Table 1),
though this correlation disappeared after controlling for multiple
testing (FDR = 0.063, Table 1). We also did not observe a
significant correlation between the enzyme activity on epirubicin
glucuronidation (p = 0.72, Table 2). This may again reflect the
limitation of our small sample size. However, to our knowledge,
it is for the first time that we observed UGT2B17 expression and
activity are positively correlated with age in children.
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It should be noted that UGT expression and enzymatic activity
are also significantly influenced by genetic variation. This is
particularly important for UGT2B17 where a polymorphism
known as copy number variation (CNV) affects the enzyme’s
transcription and activity. Our previous study also identified
novel regulatory single nucleotide polymorphisms (SNPs) for
UGT2B17 in addition to the CNV polymorphism (Liu et al.,
2014). Thus, the regulation of UGT2B17 transcription among
children can be affected by both age and genetic variation. Other
than these major factors that are involved in intrinsic drug
clearance, the degree of physiological maturation especially organ
size and blood flow are also important factors affecting drug
pharmacokinetics in children. Therefore, all these factors should
be considered for pharmacokinetic and pharmacodynamic
analyses of relevant drugs in children.
We observed that PXR and ESR1 are two TFs that modulate
UGT gene expression in people between ages of 0–25 years,
though the association is weak after FDR correction for multiple
testing. This weak association may be due to the limited
sample size in our study. Our previous study in 125 livers
encompassing the entire age range of a human lifespan (0–
81 years) demonstrated that PXR and ESR1 are highly important
transcriptional regulators of hepatic UGTs (Liu et al., 2014). Both
TFs play a key role in sensing steroids and xenobiotics (i.e.,
estrogen and progesterone as well as their metabolites) during
transcription of numerous genes, especially those involved
in drug/xenobiotic metabolism of hormonal levels. Our data
indicate that hormonal regulation may be a critical factor in
mediating the age-dependent expression of hepatic UGTs during
human development, given the known age-dependent increase
in steroid levels. It is known that progesterone is the precursor
of both estradiol and testosterone, and both estradiol and
progesterone levels significantly increase during puberty in both
boys and girls (Fadalti et al., 1999; Ankarberg-Lindgren and
Norjavaara, 2008). This is consistent with our observations about
changes in UGT expression and enzymatic activity before and
after approximately 15 years old. Therefore, the sex hormone
signaling may be at least partly involved in the regulatory
mechanism underlying age-related UGT transcription.
Our study was limited by a small sample size, which decreased
our power to detect the ontogenic changes of UGTs, especially
in early childhood, e.g., the neonates. The small sample size also
limited our capacity to investigate the interaction between genetic
and other factors, as well as the impact that this interaction might
have on UGT expression and activity. As both genetic alleles and
age are known to regulateUGT expression in the liver, elucidating
the role of this interaction will further establish the key matrix of
factors that can be used to determine the pharmacokinetics and
pharmacodynamics of UGT substrates in pediatric populations.
Our data thus warrant further investigation of these factors
within a larger and more diverse population.
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